次要结果为热退所需时间，24小时后无热持续时间，与发热有关的症状和副反应。
Secondary outcomes were time to first occurrence of normal temperature (fever clearance), time without fever over 24 hours, fever associated symptoms, and adverse effects.
在印度奥里萨邦，2006年2月27日至3月5日报告了4 904例与肌痛和头痛有关的发热病例。
In Orissa state, India, 4904 cases of fever associated with myalgia and headache have been reported between 27 February - 5 March 2006.
在第三个治疗周期后，贝伐单抗与显著增多的毒性事件有关系，特别是发热引起的粒细胞减少和肺出血。
After the third treatment cycle, bevacizumab was associated with significantly more toxic events, particularly febrile neutropenia and pulmonary hemorrhage.
应用推荐